Latest Ziopharm Oncology Inc (ZIOP) Headlines
Investors' Radars Failed to Catch ZIOPHARM (ZIOP), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:51AM CDT
ZIOPHARM has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Why ZIOPHARM (ZIOP) is Poised to Beat Earnings Estimates? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:50AM CDT
ZIOPHARM has seen a nice streak of beating earnings estimates at the previous two reports and could be a great candidate for another beat
Surging Earnings Estimates Signal Good News for ZIOPHARM (ZIOP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:37AM CST
ZIOPHARM could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Why ZIOPHARM Oncology, Inc. Zoomed Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 1:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotechnology company ZIOPHARM Oncology ...
ZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities
GlobeNewswire - Mon Mar 03, 3:37PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the company's product development activities.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
War On Poachers to Intensify
All Africa Global Media - Wed Feb 26, 12:31AM CST
THE government will use all resources at its disposal to improve anti-poaching operations and increase the number of game rangers to protect the country's wildlife from total extinction, Natural Resources and Tourism Minister Lazaro Nyalandu has said.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
Germ Cell Tumors - Pipeline Review, H2 2013
M2 - Mon Feb 17, 3:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t5hzv/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2013" report to their offering. 'Germ Cell Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Scope - A snapshot of the global therapeutic scenario for Germ Cell Tumors. - A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Germ Cell Tumors Overview Therapeutics Development Pipeline Products for Germ Cell Tumors - Overview Pipeline Products for Germ Cell Tumors - Comparative Analysis Germ Cell Tumors - Therapeutics under Development by Companies Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes Germ Cell Tumors - Pipeline Products Glance Clinical Stage Products Early Stage Products Germ Cell Tumors - Products under Development by Companies Germ Cell Tumors - Products under Investigation by Universities/Institutes Germ Cell Tumors - Companies Involved in Therapeutics Development Germ Cell Tumors - Therapeutics Assessment Drug Profiles alvocidib hydrocholride - Drug Profile palifosfamide - Drug Profile tivantinib - Drug Profile Allogeneic Tumor Cell Vaccine [celecoxib] [cyclophosphamide] - Drug Profile Combretastatin Analogs - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned ZIOPHARM Oncology, Inc. ArQule, Inc. Tolero Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ell_tumors About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PATTISON Outdoor Advertising is Proud to Present the Unique Art in Transit Programme
Marketwire Canada - Thu Feb 13, 4:59AM CST
Editors note: There is a photo associated with this press release.
ZIOPHARM Oncology to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th, 2014 at 10:00 a.m. ET at the Waldorf Astoria in New York City.
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
ZIOPHARM Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2014 at 11:30 a.m. PT at The Westin St. Francis in San Francisco, CA.
Additional Shares Purchased, Extended Collaboration, Credit Facility, Publication of Data, and Interim Results - Research Report on Karyopharm, Agios, Lannett, MacroGenics, and ZIOPHARM
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Lannett Company, Inc. (NYSE: LCI), MacroGenics, Inc. (NASDAQ: MGNX), and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Dec 20, 7:53AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray
PR Newswire - Thu Dec 19, 7:34AM CST
Editor Note: For more information about this release, please scroll to bottom.
CytRx Directors Are $3M Richer With Well-Timed Stock Option Grants
at The Street - Mon Dec 16, 6:00AM CST
CytRx directors award themselves stocks option one day before the company's stock prices soars on clinical trial results.
Global Thymus Cancer Clinical Trials Review - H2 2013
M2 - Wed Dec 11, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxl3x9/thymus_cancer) has announced the addition of the "Thymus Cancer Global Clinical Trials Review, H2, 2013" report to their offering. Thymus Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thymus Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thymus Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thymus Cancer Therapeutics Clinical Trials - Novartis AG - Nerviano Medical Sciences S.r.l. - ZIOPHARM Oncology, Inc. - Enzon Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Stanford University - Indiana University School of Medicine - Eastern Cooperative Oncology Group - Memorial Sloan Kettering Cancer Center - Shanghai Chest Hospital - Samsung Medical Center - Faculty of Pharmaceutical Sciences, Chulalongkorn University - Roswell Park Cancer Institute - Valley Health System For more information visit http://www.researchandmarkets.com/research/kx...mus_cancer
Investors' Radars Failed to Catch ZIOPHARM (ZIOP), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:51AM CDT
ZIOPHARM has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Why ZIOPHARM (ZIOP) is Poised to Beat Earnings Estimates? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:50AM CDT
ZIOPHARM has seen a nice streak of beating earnings estimates at the previous two reports and could be a great candidate for another beat
Surging Earnings Estimates Signal Good News for ZIOPHARM (ZIOP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:37AM CST
ZIOPHARM could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front
Why ZIOPHARM Oncology, Inc. Zoomed Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 1:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of biotechnology company ZIOPHARM Oncology ...
ZIOPHARM Reports Fourth-Quarter and Full-Year 2013 Financial Results and Reviews Recent Activities
GlobeNewswire - Mon Mar 03, 3:37PM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the company's product development activities.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
War On Poachers to Intensify
All Africa Global Media - Wed Feb 26, 12:31AM CST
THE government will use all resources at its disposal to improve anti-poaching operations and increase the number of game rangers to protect the country's wildlife from total extinction, Natural Resources and Tourism Minister Lazaro Nyalandu has said.
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
Germ Cell Tumors - Pipeline Review, H2 2013
M2 - Mon Feb 17, 3:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t5hzv/germ_cell_tumors) has announced the addition of the "Germ Cell Tumors - Pipeline Review, H2 2013" report to their offering. 'Germ Cell Tumors - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Germ Cell Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Germ Cell Tumors. Scope - A snapshot of the global therapeutic scenario for Germ Cell Tumors. - A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Germ Cell Tumors pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Germ Cell Tumors Overview Therapeutics Development Pipeline Products for Germ Cell Tumors - Overview Pipeline Products for Germ Cell Tumors - Comparative Analysis Germ Cell Tumors - Therapeutics under Development by Companies Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes Germ Cell Tumors - Pipeline Products Glance Clinical Stage Products Early Stage Products Germ Cell Tumors - Products under Development by Companies Germ Cell Tumors - Products under Investigation by Universities/Institutes Germ Cell Tumors - Companies Involved in Therapeutics Development Germ Cell Tumors - Therapeutics Assessment Drug Profiles alvocidib hydrocholride - Drug Profile palifosfamide - Drug Profile tivantinib - Drug Profile Allogeneic Tumor Cell Vaccine [celecoxib] [cyclophosphamide] - Drug Profile Combretastatin Analogs - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned ZIOPHARM Oncology, Inc. ArQule, Inc. Tolero Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ell_tumors About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PATTISON Outdoor Advertising is Proud to Present the Unique Art in Transit Programme
Marketwire Canada - Thu Feb 13, 4:59AM CST
Editors note: There is a photo associated with this press release.
ZIOPHARM Oncology to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, and Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 16th Annual BIO CEO & Investor Conference on Monday, February 10th, 2014 at 10:00 a.m. ET at the Waldorf Astoria in New York City.
10-Q: STARRETT L S CO
Edgar Online - Thu Jan 30, 1:40PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 12-15
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
ZIOPHARM Oncology to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 6:00AM CST
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2014 at 11:30 a.m. PT at The Westin St. Francis in San Francisco, CA.
Additional Shares Purchased, Extended Collaboration, Credit Facility, Publication of Data, and Interim Results - Research Report on Karyopharm, Agios, Lannett, MacroGenics, and ZIOPHARM
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Lannett Company, Inc. (NYSE: LCI), MacroGenics, Inc. (NASDAQ: MGNX), and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Dec 20, 7:53AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Health Care Sector Insights: ZIOPHARM Oncology, Chelsea Therapeutics Intl., Antares Pharma, and Accuray
PR Newswire - Thu Dec 19, 7:34AM CST
Editor Note: For more information about this release, please scroll to bottom.
CytRx Directors Are $3M Richer With Well-Timed Stock Option Grants
at The Street - Mon Dec 16, 6:00AM CST
CytRx directors award themselves stocks option one day before the company's stock prices soars on clinical trial results.
Global Thymus Cancer Clinical Trials Review - H2 2013
M2 - Wed Dec 11, 9:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/kxl3x9/thymus_cancer) has announced the addition of the "Thymus Cancer Global Clinical Trials Review, H2, 2013" report to their offering. Thymus Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thymus Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thymus Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Thymus Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Thymus Cancer Therapeutics Clinical Trials - Novartis AG - Nerviano Medical Sciences S.r.l. - ZIOPHARM Oncology, Inc. - Enzon Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Stanford University - Indiana University School of Medicine - Eastern Cooperative Oncology Group - Memorial Sloan Kettering Cancer Center - Shanghai Chest Hospital - Samsung Medical Center - Faculty of Pharmaceutical Sciences, Chulalongkorn University - Roswell Park Cancer Institute - Valley Health System For more information visit http://www.researchandmarkets.com/research/kx...mus_cancer
